- Abstract Number: 2677
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
- Abstract Number: 2548
NADPH Oxidase in B Cells and Macrophages Protects Against Murine Lupus by Regulation of TLR7
- Abstract Number: 2404
Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
- Abstract Number: 1152
Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets
- Abstract Number: 2446
Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study
- Abstract Number: 2320
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
- Abstract Number: 1233
Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis
- Abstract Number: 2312
National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
- Abstract Number: 0260
National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
- Abstract Number: 2038
Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection
- Abstract Number: 0258
Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020
- Abstract Number: 2399
Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization
- Abstract Number: 1872
Nationwide Analysis of Prosthetic Joint Complications with and Without Inflammatory Arthritis
- Abstract Number: 1394
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
- Abstract Number: 1747
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
- Abstract Number: 1443
Natural Course of Degenerative Lesions of the Spine on Radiographs and MRI in Axial SpondyloarthritisFollowed 10 Years in the DESIR Cohort
- Abstract Number: 0109
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
- Abstract Number: 0948
Neuronal Intestinal Dysplasia Due to Ncx Gene Deficiency Attenuates the Severity of Experimental Arthritis in Mice
- Abstract Number: 2547
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
- Abstract Number: 2406
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
- Abstract Number: 1321
Neuropsychological Evaluation of Cognitive Impairment in Patients with Rheumatic Diseases
- Abstract Number: 0239
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
- Abstract Number: 0801
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
- Abstract Number: 0507
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
- Abstract Number: 1268
Neutrophil Lymphocyte Ratio as a Novel Marker of Skin Disease Activity in Older Children with Juvenile Dermatomyositis
- Abstract Number: 0766
Neutrophil Transcriptomics in VEXAS Syndrome
- Abstract Number: 1581
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
- Abstract Number: 0185
New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
- Abstract Number: 0470
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
- Abstract Number: 1576
New Patient-Reported Outcome Measures for Early Systemic Sclerosis Using the FDA Guidance on Patient Reported Outcome Measures
- Abstract Number: 0193
New York City Lupus Clinical Trials Education Program
- Abstract Number: 1780
Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus
- Abstract Number: 0912
Next-Generation Sequencing in Molecular Genetics of Adult-Onset Still’s Disease: Data from 23 Patients and Literature Review
- Abstract Number: 0836
NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
- Abstract Number: 1114
Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
- Abstract Number: 0933
NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
- Abstract Number: 1941
No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders
- Abstract Number: 2166
Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions
- Abstract Number: 1017
Non-Adherence and Missed Appointments in Rheumatology: Pre and Post COVID-19 Pandemic Impact
- Abstract Number: 2018
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
- Abstract Number: 1125
Non-Classical Complications of Adult-Onset Still’s Disease: A Multicenter Spanish Study
- Abstract Number: 0752
Non-classical Organ Involvement in Giant Cell Arteritis
- Abstract Number: 0540
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
- Abstract Number: 0334
Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
- Abstract Number: 1808
Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients
- Abstract Number: 1532
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
- Abstract Number: 1663
Notch—mediated Fibrogenic Activation Is a Spatial Determinant of RA Treatment Response
- Abstract Number: 1504
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
- Abstract Number: 0105
Novel Autoantibodies Identified in the Antiphospholipid Syndrome
- Abstract Number: 2543
Novel IgG Degrader BHV-1300 Demonstrates the Ability to Remove Anti-bDMARD ADA and Allows for Co-administration with Fc-containing Biologics
- Abstract Number: 0633
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
- Abstract Number: 0833
Novel Loss of Function Variants in the Death Domain of Tumor Necrosis Factor Superfamily Receptor 1A (TNFRSF1A) in Children with Systemic Juvenile Idiopathic Arthritis (sJIA)
- Abstract Number: 0902
Novel Role of TYK2mechanism in SLE Pathogenesis via T Cell and B Cell Pathways
- Abstract Number: 0974
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
- Abstract Number: 0006
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
ACR Convergence 2024
November 14-19, 2024. Washington, DC.